Cas9 Stable Cell Line - T98G

The T98G-Cas9 stable cell line is a specialized genetic model derived from the human glioblastoma T98G cell line, genetically engineered to constitutively express the Cas9 nuclease. T98G is an adherent, fibroblast-like cell line isolated from a 61-year-old male, characterized by hyperpentaploid chromosome number and the ability to undergo G1 phase arrest in vitro. This characteristic makes T98G a valuable model for studying the cell cycle and cellular responses to chemotherapeutic drugs in a non-proliferative state. Integrating the Cas9 enzyme into this context ensures stable and efficient gene editing, allowing researchers to precisely manipulate the glioblastoma genome without co-transfection with Cas9-carrying plasmids, which often leads to inconsistent results in complex polyploid contexts.

Applications of the T98G-Cas9 stable cell line primarily focus on elucidating the complexities of brain cancer biology and developing innovative therapies. It is a key tool for identifying the genetic drivers of glioblastoma progression, metastasis, and resistance to standard therapies such as temozolomide and radiotherapy. Researchers used this cell line for large-scale CRISPR screening to identify genes that, when knocked out, could enhance the sensitivity of tumor cells to specific drugs or inhibit their invasiveness. Furthermore, the T98G-Cas9 cell line can serve as a powerful platform for validating the functional impact of somatic mutations in patients, thereby constructing homology models to study the molecular mechanisms of glioma drug resistance.